2026 RNDS | Closing Remarks @wearesrna
2026 RNDS | Closing Remarks  @wearesrna
Uploaded October 2026 | Updated November 2026, 3 hours ago
In this closing session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, and SRNA Executive Director GG deFiebre closed the three-day symposium [00:00:05]. Dr. Levy led applause for the speakers, the SRNA staff who put the event on, and everyone who stayed to the end [00:00:05]. GG thanked those attending online and in person, and the presenting sponsors Alexion, Amgen, Genentech and UCB, along with Kennedy Krieger and Grapevine [00:01:00]. Attendees used their phones to share one-word takeaways, including empowerment, validation, hope and community [00:01:39]. They also answered how they felt after three days, and Dr. Levy ended with one word of his own: thank you [00:03:05].

Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.

00:00 Welcome and Applause
00:34 Thanks to Everyone Who Stayed
01:00 Thanks from SRNA and Sponsors
01:39 Biggest Takeaway Poll
03:05 How Are You Feeling
04:06 One Word for RNDS
04:35 Final Thanks
2026 RNDS | Closing Remarks2024 RNDS | NMOSD and MOGAD Clinical Trials1214. Self Identity and Finding Meaning Following DiagnosisCommunity Meets Clinic 304. Dr. Ayşe Altıntaş2025 RNDS en Español | Bienvenida2024 Stronger Together | Journey Together: Reflecting and Shaping the Future2017 RNDS | Welcome and Goals2023 RNDS en Español | Una conversación con nuestros aliados de la industria sobre apoyo y recursos2025 RNDS en Español | Trastornos neuroinmunes poco frecuentes: mielitis transversa (MT)2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse2025 RNDS | Upcoming therapies for MOGAD and NMOSD: Long-term therapeutics1311.  Understanding Myelitis: Efforts to Update Diagnostic Criteria
SRNA |

2026 RNDS | Closing Remarks

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER